CopyMark Law Group
4.9/5
Drawing for LUMITIN

USPTO serial 79149533

LUMITIN

Reviewed by CopyMark Law Group

Reg. 4741346Status 404
Filing date
Status date
Registration date
May 26, 2015
Examiner
POLZER, NATALIE M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LUMITIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alex Patel

Alex Patel PATEL & ALMEIDA, P.C.16830 VENTURA BLVD, SUITE 360Encino, CA 91436UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Medicines for humans used for the treatment of choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-relatedmacular degeneration, retinal vein occlusion, neoplastic disease and cancer, angiogenesis disease; Pharmaceutical preparations for the treatment of diabetes, cardiovascular disease and disorder, neoplastic disease and disorder, cancer, disease and disorder of immune system, angiogenesis disease and disorder, ophthalmic diseases and disorder, mental disease and disorder, aged-related macular degeneration; Injectable preparations for medical use, namely, for the treatment of oculopathy, choroidal neovascularization induced by high myopia, macular edema induced by retinal vein occlusion, diabetic macular edema, wet age-related macular degeneration accompanied by very low vision acuity, the inhibition of neovascularization, back-of-the-eye neovascularization, aged-related macular degeneration, retinal vein occlusion, neoplastic disease, angiogenesis disease and cancer; Aqueous formula, namely, water-based pharmaceutical preparations for the treatment of cardiovascular disease and disorder, neoplastic disease and disorder, disease and disorder of immune system, ophthalmic diseases and disorder, inflammation; Biochemical drugs and preparations for medical use, namely, for the prevention, treatment and alleviation of angiogenesis disease, oculopathy, neoplastic disease, cancer, all of the foregoing being available by prescription onlySECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 18, 2024DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Oct 18, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 31, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Sep 22, 2022XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Sep 22, 2022XXCRGENERIC MADRID TRANSACTION CREATED—
Aug 10, 2022INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 10, 2021C71TCANCELLED SECTION 71—
Jun 5, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 26, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 9, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 23, 2015FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 23, 2015FIMPFINAL DISPOSITION PROCESSED—
Aug 26, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 26, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 10, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 10, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 18, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 31, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 29, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 8, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 8, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 8, 2015ALIEASSIGNED TO LIE—
Jan 6, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 22, 2014RFNTREFUSAL PROCESSED BY IB—
Aug 2, 2014MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 1, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 1, 2014RFRRREFUSAL PROCESSED BY MPU—
Aug 1, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 31, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 29, 2014DOCKASSIGNED TO EXAMINER—
Jul 29, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 24, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance